Chemokine receptor 5 (CCR5) inhibitors, such as Maraviroc, represent a novel class of antiretroviral therapeutics designed to prevent HIV-1 infection of CD4+ T cells via the inhibition of the CCR5 receptor [28]. Here, CCR5 is linked to HIV-1 infection.